In the News

April 04, 2022
STAT News

One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.

April 04, 2022
PharmaPhorum

AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”

April 04, 2022
Reuters

A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

April 04, 2022
Wall Street Journal

A fund that plans to invest $1 billion in antibiotics companies has made its first two deals, backing startups aiming to tackle AMR in different ways. AMR Action Fund launched in 2020 to finance smaller biotechnology companies with antimicrobial drugs in clinical trials, bridging what it says is a funding gap between early research and regulatory approval.

April 04, 2022
Bloomberg

A $1 billion fund backed by some of the world’s biggest drugmakers has made its first two investments in a bid to spur the development of new antibiotics and counter the rising threat of superbugs.

April 04, 2022
Endpoint News

The AMR Action Fund has made its first two investments in the hopes of addressing the looming threat of antimicrobial resistance.

April 04, 2022
FinSMEs

Venatorx Pharmaceuticals sold shares of its Series C Preferred Stock in a financing of undisclosed amount. Proceeds from the financing will be used to support the company as it advances its novel antibacterial portfolio through the drug development process.

April 04, 2022
CIDRAP

The two companies represent different approaches to combating antimicrobial resistance (AMR). One is a more traditional antibiotic approach, while the other actually predates antibiotics.

April 04, 2022
Healio | Infectious Disease News

A $1 billion public-private partnership seeking new antibiotics announced its first investments. The AMR Action Fund said it has invested in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.

April 04, 2022
FierceBiotech

The AMR Action Fund, backed by Big Pharmas such as Pfizer, Eli Lilly, Bayer and more, has selected the first beneficiaries of its $1 billion fund to address drug-resistant bacterial infections: Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.

March 14, 2022
Medical Dialogues

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.

March 14, 2022
FDA News
March 12, 2022
AMR Insights

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

March 11, 2022
pharmaphorum

Venatorx Pharmaceuticals has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance.

March 10, 2022
Philadelphia Business Journal

A Chester County pharmaceutical company on Thursday announced positive results for its lead new drug candidate, an antibiotic under development to treat complicated urinary tract infections.

March 10, 2022
ContagionLive

Complicated Urinary Tract Infections can be very challenging for clinicians to treat. These UTI do not respond to traditional, first-line therapies, and due to the nature of these bacterial infections, and patients' frequent underlying health conditions, they can be more susceptible to complications including sepsis.

March 10, 2022
BioSpace

Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.

March 10, 2022
FierceBiotech

Venatorx Pharmaceuticals’ mission to start restocking the thinning cupboard of antibiotics has advanced. With its experimental candidate hitting the primary endpoint in phase 3, Venatorx is preparing to file for FDA approval in patients with urinary tract infections by the end of the year.

March 10, 2022
BioWorld

The beta-lactam/beta-lactamase inhibitor combo surpassed noninferiority to standard meropenem in the phase III trial CERTAIN-1, demonstrating statistical superiority for the trial's composite endpoint of microbiologic and clinical response.

November 18, 2021
ContagionLive

ONE BIG QUESTION: "Do you get the sense that the overall medical community understands the magnitude of the problem of antimicrobial resistance?" ContagionLive marks the start o World Antimicrobials Awareness Week with these insights...
Archive: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016